Evonik has launched a series of new formulations of L-Ornithine-L-Aspartate (LOLA) at CPhI in Madrid. The new formulations aim to simplify the administration of this therapeutic agent for liver diseases. LOLA supports the reduction of ammonia concentrations in patients with a damaged liver, a problem globally on the rise. The existing delivery forms were injectable or powders, which can be difficult to prepare and unpleasant to drink.   
 
“Our aim was to increase the acceptance of patients by delivering a product with significantly improved mouth feel and taste,” explains Dr. Ashish Guha, responsible R&D manager for the new developments. In addition, the company has changed the crystalline structure of the product to speed up disintegration in water and to make the formulation drinkable faster. The new offering consists of effervescent tablets and granules, mouth-dissolving granules, chewable tablets as well as tea bags.   
 
Osama Arabi-Katbi, who is commercially responsible for the new launches, emphasizes, “We have taken the different market needs into account. The formulations can easily and quickly be launched into the market, as we can offer all necessary regulatory approvals.”